Imipenem-Cilastatin sodium hydrate

Imipenem-Cilastatin sodium hydrate Chemische Eigenschaften,Einsatz,Produktion Methoden

• Clinical Use

  Antibacterial agent

• Arzneimittelwechselwirkung

  Potentially hazardous interactions with other drugs
  Antiepileptics: reduced valproate concentration - avoid.
  Antivirals: convulsions reported with concomitant administration of ganciclovir and valganciclovir.
  Ciclosporin: variable reports of increase / no change in ciclosporin levels, and of neurotoxicity.

• Stoffwechsel

  When administered alone, imipenem is metabolised in the kidneys by dehydropeptidase-I, an enzyme in the brush border of the renal tubules, to inactive, nephrotoxic metabolites, with only about 5 to 40 or 45% of a dose excreted in the urine as unchanged active drug. Cilastin inhibits the metabolism of imipenem. When given with cilastatin about 70% of an intravenous dose of imipenem is recovered unchanged in the urine within 10 hours. Cilastatin is also excreted mainly in the urine, the majority as unchanged drug and about 12% as N-acetyl cilastatin. Less than 1% of imipenem is excreted via the bile in the faeces.

Imipenem-Cilastatin sodium hydrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(57)Suppliers

92309-29-0, Imipenem-Cilastatin sodium hydrate Verwandte Suche: